Situation Assessment

• C4 Therapeutics is a private biotech with a novel targeted protein ​ degradation platform and pipeline of pre-IND therapeutics in oncology​
• C4 Therapeutics was seeking funding to advance the current pipeline to proof-of-concept and position the company for a successful IPO​
• At the time of engagement, C4 Therapeutics had received a term sheet for Perceptive Advisors for a $115M+ Series B round​
• LW was engaged to prepare marketing materials, advise on the financing, build out the syndicate, and coordinate the closing

Key Activities

• Prepared high-impact marketing materials distilling complicated science ​ into an understandable management presentation and teaser​
• Conducted targeted outreach campaign to top-tier global and regional life-science focused investors to build out the syndicate in April 2020​
• Hosted a fully virtual roadshow with investors and led investors through virtual due diligence process​
• Conducted financial analysis to guide the deal sizing and pricing​
• Provided extensive guidance on deal dynamics and worked in collaboration with legal teams to drive financing to close

Successful Outcome

• C4 Therapeutics successfully raised an ​upsized $150M Series B financing co-led by Perceptive Advisors and Cobro Opportunity Fund with a global syndicate of leading life sciences investors ​
• In volatile funding environment, Locust Walk was integral to guiding investors and the Company to a successful closing of the financing